PepGen has priced a public offering of 25 million common shares at $5 per share, providing expected gross proceeds of $125 million before underwriting discounts, commissions, and other expenses.
The clinical-stage biotechnology company is selling all of the shares included in the offering. It granted the underwriters a 30-day option to purchase as many as 3.75 million additional shares at the public offering price.
If that option is exercised in full, the company would receive another $18.75 million in gross proceeds before expenses, increasing the offering’s potential total to $143.75 million.
PepGen plans to use the net proceeds to support the continuing clinical development of its product candidate, along with working capital and other general corporate purposes.
The company’s principal clinical program is PGN-EDODM1, an investigational treatment for myotonic dystrophy type 1. The drug uses PepGen’s Enhanced Delivery Oligonucleotide technology, which combines therapeutic oligonucleotides with cell-penetrating peptides.
PepGen designed the platform to improve cellular uptake and activity in tissues that have historically been difficult for oligonucleotide medicines to reach.
The financing follows the release of positive Phase 2 results from the 10 mg/kg cohort of the FREEDOM2-DM1 study. PepGen reported improvements in RNA splicing and several functional measurements and has fully enrolled a higher-dose cohort.
The public offering will increase the number of outstanding shares, diluting existing shareholders. However, the additional capital could extend PepGen’s operating runway and support clinical, regulatory, manufacturing, and corporate activities.
Leerink Partners, Stifel, and Guggenheim Securities are acting as joint bookrunning managers. Oppenheimer is serving as passive bookrunner, while H.C. Wainwright is lead manager.
The offering is expected to close on or about November 13, subject to customary closing requirements.

